Non-invasive AI Vektor Medical offers vMap, a non-invasive, AI-powered arrhythmia localization solution that is FDA-cleared and CE-marked, presenting a compelling upsell to hospitals and clinics seeking advanced diagnostic tools with proven regulatory clearance.

Accelerated adoption Recent leadership additions including a new CFO and VP of Operations alongside ongoing sales leadership hires suggest a push to scale commercial adoption, creating opportunities for enterprise accounts, pilot programs, and expanded deployment with cardiology groups.

Strategic funding A $29M funding base and a $16M Series A in 2024 from TVM Capital and Solas BioVentures signal validated growth potential, which can be leveraged when engaging potential customers about long-term partnerships, favorable financing options, and future product roadmap alignment.

Event exposure Participation in major industry events such as Heart Rhythm 2025 and active press coverage provide conversational hooks for outreach, enabling SDRs to reference live demonstrations, case studies, and momentum in the market to engage cardiology departments.

Clinical impact By improving accuracy and speed in localizing arrhythmia drivers across all heart chambers, vMap positions Vektor Medical for use in diverse clinical settings that require efficient, precise mapping, creating cross-sell potential with electrophysiology labs, hospital systems, and integrated care networks.